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Immortality is an essential characteristic of cancer cells; our 
recent transcriptomic study of in vitro immortalization of hu-
man mammary epithelial cells (HMEC) reported on the epi-
genetic silencing of the long noncoding RNA (lncRNA) Mor-
tal Obligate RNA Transcript (MORT; alias ZNF667-AS1) during 
the transition of the cells from mortal to immortal [1]. MORT 
is expressed in all normal, mortal human cell types analyzed 
to date, but is epigenetically silenced in the majority of human 
cancers and human cancer cell lines [1]; there is little evidence 
suggesting genetic mechanisms of inactivation. The experi-
mental finding that MORT is silenced at the mortal-immortal 
boundary of HMEC, prior to and independent of malignant 
conversion, suggests that MORT silencing is an early epigene-
tic event in human carcinogenesis that occurs prior to malig-
nant transformation. Since a large fraction of clinical carcino-
ma in situ lesions—including ductal carcinoma in situ (DCIS) 
[2]—show evidence of immortality in the absence of a frank 
malignancy [3-5], it is predicted that the epigenetic silencing 
of MORT is a common feature of this premalignant state. 
Breast cancer is a heterogeneous disease, but our previous 
analysis was not focused on MORT silencing in individual 
breast cancer subtypes and could not reveal if MORT silencing 
was an early event in clinical carcinogenesis.
Using molecular and clinical data from publicly accessible 
databases, we set out to evaluate the epigenetic and transcrip-
tional status of MORT in premalignant tumors. Consistent 
with previous laboratory studies, our data analysis shows that 
DNA methylation-mediated silencing of MORT is found in 
both breast DCIS and colonic adenomas; this moves the tim-
ing of MORT epigenetic silencing further back to clinical pre-
malignant conditions. The epigenetic silencing of MORT in 
premalignancy is maintained throughout progression towards 
the invasive and metastatic disease; no evidence was found for 
genetic mechanisms of MORT silencing. The DNA methyla-
tion-mediated silencing of MORT is significantly associated 
with luminal, receptor positive breast cancer; in contrast, basal 
triple negative breast cancers do not generally display MORT 
methylation or gene silencing. These early epigenetic events 
and the cellular mechanisms that they influence may provide 
new targets for cancer prevention or treatment.
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Immortality is an essential characteristic of cancer cells; a recent 
transcriptomic study of epithelial cell immortalization has linked 
epigenetic silencing of the long noncoding RNA Mortal Obligate 
RNA Transcript (MORT; alias ZNF667-AS1) to this process. This 
study evaluated the epigenetic and transcriptional state of 
MORT in two premalignant conditions—ductal carcinomas in 
situ and colon adenomas. Results show that MORT silencing is 
an early epigenetic event in human carcinogenesis, likely occur-
ring near the point where premalignant cells gain immortality; 
this epigenetic silencing is maintained throughout malignant 
transformation and metastatic growth. Additional associations 
between MORT loss and clinical and molecular features of 
breast tumors showed that silencing of MORT occurs predomi-
nantly in luminal, receptor-positive breast cancer; is associated 
with overexpression of CCND1 and mutations of GATA3; and is 
negatively correlated with TP53 mutations. Taken in toto, MORT 
silencing occurs early in breast carcinogenesis, probably during 
cellular immortalization, and precedes the development of inva-
sive luminal breast cancer.
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DNA methylation (Illumina HumanMethylation450), gene 
expression (RNASeqV2), genetic (copy number variation, 
mutation), and available clinical data for breast tumor samples 
were downloaded from The Cancer Genome Atlas (TCGA). 
All data were analyzed with the R programming software [6] 
using custom scripts. MORT mean β values and mean reads 
per kilobase per million (RPKM) values were calculated as 
described previously [1]. Only nonsilent mutations were con-
sidered in the gene mutation analysis. The Spearman’s rank 
correlation coefficient (rho) was calculated using the cor.test 
function. All tests between groups were performed using the 
wilcox.test function. When appropriate, multiple testing cor-
rections were performed according to Benjamini and Hoch-
berg [7]. PAM50 tumor subtype classification was used as de-
scribed previously [8]. In addition to TCGA, further Illumina 
HumanMethylation450 datasets for breast (GSE60185 [9], 
GSE66313 [10], and GSE58999 [11]) and colon (GSE48684 
[12] and GSE77954 [13]) cancer samples were downloaded 
from Gene Expression Omnibus (GEO). Where necessary, M 
values were converted to β values using the formula 2M/
(1+2M). The reduced representation bisulfite sequencing 
(RRBS) and RNA-seq DCIS datasets (GSE69993 and 
GSE69240 [14]) were downloaded from GEO. For RRBS, the 
mean methylation value for the 19 covered CpGs within the 
MORT CpG island promoter was used for analysis. 
We have previously reported that MORT is epigenetically 
silenced by DNA methylation in breast cancer and 14 out of 
16 other common human tumors investigated. To determine 
the potential timing of MORT silencing during human breast 
carcinogenesis, we analyzed the DNA methylation state of the 
MORT promoter in DCIS samples from two published, inde-
pendent cohorts [9,10]. The results show a significant increase 
in DNA methylation of the MORT promoter in DCIS com-
pared with normal samples (Figure 1A, B); MORT methyl-
ation did not appear to increase further during progression 
from DCIS to invasive breast cancer (IBC) (Figure 1A), nor 
during progression to the metastatic disease, as illustrated by 
data from a cohort [11] of pairs of primary and metastatic 
Figure 1. MORT gene silencing is early event in cancer. (A, B) DNA methylation of the MORT promoter in two independent cohorts of breast ductal 
carcinoma in situ (DCIS) patients. (C) DNA methylation of the MORT promoter in 44 pairs of primary breast tumors and lymph node metastasis. (D) 
DNA methylation of the MORT promoter as determined by reduced representation bisulfite sequencing in a DCIS cohort. (E, F) DNA methylation of 
the MORT promoter in two independent cohorts of colon adenomas and carcinomas. All data except (D) were obtained using the Illumina Human 
Methylation 450 platform. Where more than two groups are presented the p-value is for in situ lesions versus normal samples. 
IBC= invasive breast cancer.
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breast tumors (Figure 1C). A third cohort of DCIS, analyzed 
by RRBS and RNA-seq [14], also showed a significant increase 
in MORT methylation (Figure 1D) and MORT silencing in a 
substantial portion of the samples (Supplementary Figure 1, 
available online). Together, these results show that MORT si-
lencing is an early epigenetic event that occurs during human 
breast carcinogenesis.
We extended our analysis of premalignant lesions and ana-
lyzed the DNA methylation state of the MORT promoter in 
two independent cohorts of colon adenoma samples [12,13]. 
Although not equivalent to DCIS, colonic adenomas are early 
premalignant lesions in colorectal cancer and therefore might 
display MORT silencing if MORT silencing occurs early in 
carcinogenesis. The DNA methylation level of the MORT pro-
moter in both adenoma cohorts was significantly higher than 
in normal colon samples; there were no further increases in 
MORT methylation throughout progression of the adenoma 
to invasive colon cancer, similar to the results for DCIS and 
IBC (Figure 1E, F). These results broaden the range of prema-
lignant conditions where MORT is silenced and provide add-
itional evidence that MORT silencing is an early epigenetic 
event in human carcinogenesis.
Because breast cancer is a heterogeneous disease, we sought 
to identify any associations between MORT loss and other 
clinical and molecular features of breast tumors. Figure 2A 
presents analysis performed to assess whether gene deletion is 
an additional mechanism of MORT loss in cancer, in addition 
to aberrant DNA methylation. The results show that MORT 
loss rarely occurs due to gene deletion (Figure 2A). MORT 
loss is therefore predominantly due to epigenetic silencing 
and increased DNA methylation of the MORT promoter; 
MORT promoter methylation is a good indicator of MORT si-
lencing that could be used as a surrogate for MORT loss in 
samples where expression data are not available. When we 
tested the association between MORT methylation and clin-
ical variables, we found a strong link between MORT methyl-
ation and the presence of hormone receptors. Tumors positive 
for individual receptors have a much higher frequency of 
MORT promoter methylation (Figure 2B-D) and MORT si-
lencing (Supplementary Figure 2A-C, available online). In 
contrast, triple negative tumors have a low frequency of 
MORT methylation (Figure 2E) and near normal MORT RNA 
levels (Supplementary Figure 2D, available online). These data 
predict that MORT is predominantly silenced in luminal 
breast cancers; indeed, when we classified the breast tumors 
into subtypes according to PAM50 [15], luminal B, luminal A, 
and human epidermal growth factor receptor 2 (HER2)-en-
riched tumors had a large proportion of MORT methylation, 
while basal-like tumors showed no significant difference in 
MORT methylation or expression compared to normal con-
trol samples (Figure 2F, Supplementary Figure 2E, available 
online). Since some breast cancer subtypes are linked to age, 
we analyzed the relationship between MORT level and patient 
age. There is a moderate but notable increase in MORT meth-
ylation and decrease in MORT expression in tumors from pa-
tients over 60 years old (Figure 2G, Supplementary Figure 2F, 
available online), which is consistent with evidence of higher 
incidence of luminal tumors in older women [16]. Together, 
these results indicate that epigenetic silencing of MORT oc-
curs predominantly in luminal, receptor-positive breast can-
cers.
We investigated potential associations between MORT 
methylation and genetic features in breast tumors. When we 
correlated MORT methylation with the copy number varia-
tion data on the whole genome scale, amplification of a locus 
containing genes CCND1 and ORAOV1 on chromosome 11 
showed the strongest positive correlation (rho = 0.28, adj. 
p= 4.95e–11) with MORT promoter methylation (Figure 2H). 
Of these two amplified genes, only the CCND1 transcript level 
was significantly negatively correlated with the MORT tran-
script level (rho= –0.35, adj. p= 8.01e–31). CCND1 is a known 
cancer driver linked to luminal tumors [8] and therefore its 
overexpression, which inactivates the RB pathway [17], might 
be also implicated in MORT silencing. Finally, we analyzed the 
links between MORT methylation and mutations in 23 genes 
frequently mutated in breast cancer [8]. Mutations in two of 
these genes were strongly linked to the level of MORT methyl-
ation. Mutation of TP53 is negatively correlated to MORT 
methylation (Figure 2I)—tumors carrying a TP53 mutation 
usually have normal levels of MORT (Supplementary Figure 
2G, available online). GATA3 is frequently mutated in tumors 
that have reduced MORT expression (Supplementary Figure 
2H, available online)—there is a positive correlation between 
GATA3 mutation and MORT methylation (Figure 2J). This is 
consistent with evidence showing that TP53 mutations are en-
riched in basal-like triple negative tumors, while GATA3 mu-
tations are found predominantly in luminal tumors [8]. Over-
all, these findings suggest that MORT silencing in luminal 
breast tumors is connected to overexpression of CCND1. The 
lack of MORT silencing in basal tumors that frequently carry 
TP53 mutations indicates that MORT might act in a pathway 
that requires functional TP53, as the cells with nonfunctional 
TP53 can “afford” to express MORT and become immortal. 
The dissociation between TP53 mutations and MORT silenc-
ing is consistent with the in vitro immortalization model used 
in the discovery of MORT, where the immortal HMEC re-
tained wild-type TP53 [18].
Overall, our analysis found that, as predicted from the in vitro 
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model of HMEC immortalization, aberrant methylation of 
the MORT CpG island promoter occurs early in human breast 
carcinogenesis, likely at or near the point where premalignant 
cells gain immortality; this epigenetic silencing is maintained 
throughout malignant transformation and metastatic growth. 
In breast cancer, MORT gene silencing occurs predominantly 
in hormone receptor positive luminal tumors, while triple 
negative basal-like tumors usually show normal levels of 
Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted 
versus MORT copy number. DNA methylation of the MORT promoter in receptor negative and receptor positive tumors estrogen receptor (ER) (B), 
progesterone receptor (PR) (C), and human epidermal growth factor receptor 2 (HER2) (D). (E) DNA methylation of the MORT promoter in triple nega-
tive (TN) tumors, tumors positive for at least one receptor and a group of normal samples (p-value is for contrast TN vs. receptor (+) tumors). (F) DNA 
methylation of the MORT promoter in breast tumors classified into subtypes according to PAM50 (p-values are for contrast of individual tumor sub-
types vs. normal). (G) DNA methylation of the MORT promoter in samples from patients >60 years of age compared to those from patients ≤60. (H) 
Association between amplification of the cyclin D1 locus and DNA methylation of the MORT promoter. (I) DNA methylation of the MORT promoter in 
samples with wild type TP53 compared to samples with mutated TP53. (J) DNA methylation of the MORT promoter in samples with wild type GATA3 
compared to samples with mutated GATA3. 
RPKM=reads per kilobase per million; CN=copy number; WT=wild type.
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MORT expression. Thus, taken in toto, these results are consis-
tent with MORT silencing occurring early in breast carcino-
genesis, during cellular immortalization, and before the devel-
opment of luminal IBC. Delineating the molecular functions 
of the MORT lncRNA could provide new strategies for ther-
apeutic or chemopreventive interventions.
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